FINWIRES · TerminalLIVE
FINWIRES

$LGND

10 stories mentioning LGNDUpdated 4d ago

Every FINWIRES story that references LGND, newest first.

What are analysts saying about LGND?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on LGND?

Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,430,434, According to a Recent SEC Filing

Andrew Reardon, Chief Legal Officer & Secretary, on September 03, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,430,434. Following the Form 4 filing with the SEC, Reardon has control over a total of 36,514 common shares of the company, with 36,514 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000137/xslF345X05/edgardoc.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,444,951, According to a Recent SEC Filing

Andrew Reardon, Chief Legal Officer & Secretary, on August 03, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,444,951. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,514 common shares of the company, with 41,514 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/xslF345X05/edgardoc.xml

$LGND
Wire

Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase

Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday.XOMA Royalty shareholders received $39 in cash per share and one non-transferable contingent value right tied to a portion of proceeds from certain pending litigation, the company said.Ligand said the acquisition adds seven commercial products, 14 late-stage development programs and more than 100 development and commercial-stage assets.The company said the transaction is expected to add about $0.50 per share and $1.50 per share to its projected adjusted earnings per share in 2026 and 2027, respectively.Ligand said it expects to provide an updated five-year outlook at its Investor Day on Dec. 8.Following the closing, XOMA Royalty's common stock stopped trading on the Nasdaq Global Market, the company said.Price: $307.59, Change: $-1.66, Percent Change: -0.54%

$LGND$XOMA
Wire

Ligand Pharmaceuticals Plans $550 Million Convertible Notes Offering Due 2031

Ligand Pharmaceuticals (LGND) intends to raise $550 million through a private placement of convertible senior notes due 2031, the company said Monday.The company said it expects to grant initial purchasers a 13-day option to purchase up to an additional $82.5 million of notes.Ligand said it will use part of the proceeds for hedging transactions and up to $75 million for share buybacks to offset dilution, with the remainder for general corporate purposes, including investing in complementary businesses, companies, products and technologies.Shares of the company were down 3% in premarket trading.

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $544,830, According to a Recent SEC Filing

Stephen L Sabba, Director, on June 16, 2026, sold 2,145 shares in Ligand Pharmaceuticals (LGND) for $544,830. Following the Form 4 filing with the SEC, Sabba has control over a total of 33,629 common shares of the company, with 33,629 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/xslF345X05/tm2618247-1_4seq1.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,651,320, According to a Recent SEC Filing

Jason Haas, Director, on June 12, 2026, sold 6,461 shares in Ligand Pharmaceuticals (LGND) for $1,651,320. Following the Form 4 filing with the SEC, Haas has control over a total of 4,981 common shares of the company, with 4,981 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/xslF345X05/edgardoc.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing

Andrew Reardon, Chief Legal Officer & Secretary, on June 01, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,135,316. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,382 common shares of the company, with 41,382 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/xslF345X05/edgardoc.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $563,080, According to a Recent SEC Filing

John W Kozarich, Director, on May 01, 2026, sold 2,501 shares in Ligand Pharmaceuticals (LGND) for $563,080. Following the Form 4 filing with the SEC, Kozarich has control over a total of 41,786 common shares of the company, with 41,786 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/xslF345X05/edgardoc.xml

$LGND
Wire

RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating

Ligand Pharmaceuticals (LGND) has an average rating of buy and mean price target of $257.44 according to analysts polled by FactSet.Price: $218.14, Change: $+7.81, Percent Change: +3.71%

$LGND
Sectors

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.

$IBB$LGND$OGN$ORKA$XLV$XOMA

Track with the FINWIRES app suite

FolioX
FolioX
Track LGND in your portfolio
WheelAI
WheelAI
Analyze LGND options with the wheel strategy
StockInsider
StockInsider
See market sentiment on LGND